Endpoints News

Biogen Stops Part of an MS Trial; Merck Reports More Enflonsia Data

Biogen announced it is halting the combination‑therapy arm of its multiple sclerosis (MS) trial after interim data showed insufficient efficacy and safety concerns. The decision pauses enrollment in the experimental regimen while the company continues evaluating its monotherapy components. Meanwhile,...

Altesa Raises $75M for Oral Respiratory Med

Altesa Raises $75M for Oral Respiratory Med

Altesa announced a $75 million fundraising round to develop its oral respiratory medication. The capital will support further clinical development and commercialization efforts.

Faeth Goes Public in Merger with Sensei, Nets $200M in Stock Sale

Faeth Goes Public via Merger with Sensei, Raising $200M

Faeth announced its public listing through a merger with Sensei, generating $200 million from a stock sale. The transaction marks Faeth's entry into the public markets.

Six Biotech Companies File for HKEX IPOs

Six biotechnology firms have filed for initial public offerings on the Hong Kong Stock Exchange, signaling a push into Asian capital markets. The filings were announced on February 17, 2026.

Gilead Gets Cancer Drug From China-Based Genhouse for $80M Upfront

Gilead Sciences announced it will acquire the worldwide rights to an oral cancer therapy from China‑based Genhouse Bio, paying an $80 million upfront fee. The deal comes as Genhouse prepares for a Hong Kong IPO, positioning the drug for rapid global...

Pentagon Adds, Then Withdraws, WuXi AppTec to Chinese Military List

The Pentagon briefly placed WuXi AppTec, a major Chinese contract research organization, on its list of firms that support the People’s Liberation Army, then withdrew the designation hours later without explanation. The move occurred amid intensified U.S. scrutiny of Chinese...

Lilly Appeals Retatrutide Classification Ruling in Case that Could Impact Compounders

Eli Lilly has filed a notice of appeal challenging the FDA’s classification of its experimental obesity injection, retatrutide. The agency labeled the product as a new molecular entity, granting it a 12‑year data exclusivity period. Lilly argues the classification is incorrect...

Epigenetic Editing Startup Moonwalk Shifts Focus to siRNA for Obesity

Moonwalk Biosciences, founded by CRISPR pioneer Feng Zhang and former Illumina CTO Alex Aravanis, announced a strategic pivot from epigenetic editing to siRNA‑based obesity therapies. The company secured a $120 million Series A round to fund the new platform, which targets liver‑expressed...

Moderna's Flu Shot Dilemma Muddies 2028 Break-Even Guidance

Moderna’s chief financial officer indicated that the company cannot yet confirm whether its 2028 cash‑flow break‑even goal will hold, as the outlook for its seasonal flu vaccine remains uncertain. The flu shot, once expected to be a steady revenue stream,...

Lilly Stockpiles $1.5B Worth of Weight Loss Pill Ahead of US Approval

Eli Lilly has amassed roughly $1.5 billion worth of its experimental obesity drug orforglipron. The company began stockpiling the product months before the U.S. Food and Drug Administration is expected to grant approval later this year. Orforglipron, a GLP‑1 receptor agonist, joins...

Immunic's Private Placement; Vertex's Cystic Fibrosis Data in Young Kids

Immunic announced an oversubscribed private placement raising up to $400 million to fund its shift toward a commercial‑stage biotech. The capital injection will support late‑stage development programs and accelerate the search for a new chief executive officer. Meanwhile, Vertex Pharmaceuticals disclosed...

Paul Hudson Couldn’t Quite Get Sanofi over the Hump; PROTAC Developer Arvinas Appoints CEO

Paul Hudson has struggled to revitalize Sanofi’s R&D engine despite a series of high‑profile acquisitions since becoming CEO in 2019. The French group’s pipeline has underperformed, and recent buyouts have failed to deliver the expected boost in innovative drug candidates....

Gilead Acquires Global Rights to Genhouse Bio's Oral Cancer Drug for $80M

Gilead announced it will acquire the global rights to an oral cancer drug from China-based biotech Genhouse Bio, paying $80 million upfront. The deal expands Gilead's oncology pipeline as Genhouse prepares for a Hong Kong IPO.

Isomorphic Claims Major Advance with New AI Drug Design Engine

Isomorphic Labs, the DeepMind spin‑off behind AlphaFold 3, announced a new AI‑driven drug design engine that builds on its protein‑structure predictions. The platform claims to generate novel small‑molecule candidates up to ten times faster while achieving sub‑nanomolar binding‑affinity accuracy. Early validation...

ILiAD Raises $115M Round to Advance Whooping Cough Vaccine

ILiAD Biotechnologies announced an oversubscribed $115 million Series B financing round to accelerate development of its next‑generation whooping cough (pertussis) vaccine. The capital will fund pivotal Phase 3 clinical trials, aiming to demonstrate superior efficacy and longer‑lasting immunity compared with current acellular vaccines....

AbbVie, AstraZeneca Lose Appeal in Louisiana 340B Contract Pharmacy Fight

A U.S. appeals court upheld Louisiana's law that restricts how 340B‑discounted drugs can be dispensed through contract pharmacies. The ruling rejected the challenge mounted by AbbVie and AstraZeneca, marking another defeat for drugmakers contesting state oversight of the federal 340B...

NIH Stops Low-Dose Xarelto Arm of Large Stroke Study Due to Safety Concerns

The National Institutes of Health has stopped the low‑dose Xarelto arm of a large, multi‑center stroke trial after an interim safety analysis revealed excess bleeding. The study, which enrolled roughly 5,000 patients with recent ischemic stroke, was testing rivaroxaban 2.5 mg...

Shanghai's Cascade Gets $72M to Pursue MASH, Obesity and Diabetes Drugs

Shanghai‑based Cascade Pharmaceuticals announced a financing round of roughly 500 million yuan ($72 million). The capital will fund the development of novel therapeutics targeting metabolic dysfunction‑associated steatohepatitis (MASH), obesity and type‑2 diabetes. Cascade joins a growing cohort of private biotech firms receiving...

CSL’s Paul McKenzie Out, as Gordon Naylor Named Interim CEO

CSL Limited announced that CEO Paul McKenzie will step down immediately after more than five years with the Australian biotech group. The board appointed Gordon Naylor, a veteran pharma executive, as interim chief executive. The decision reflects the board’s view...

AstraZeneca’s Obesity Pill Hits in Phase 2, Key Cancer Trials Pushed Back

AstraZeneca announced that its oral GLP‑1 candidate elecoglipron achieved its primary efficacy endpoints in two Phase 2 obesity studies. The trials demonstrated statistically significant weight loss and a favorable safety profile, positioning the drug as a potential first‑in‑class oral therapy. Simultaneously,...

'Bat-Sh*t Crazy': Biopharma Leaders Unload on Regulatory Chaos

The provided excerpt contains only the title and a brief introductory sentence of an article about biopharma executives criticizing regulatory complexity, without the full body text. Consequently, no substantive details about specific comments, companies, regulatory issues, or market impacts are...

Cascade Pharmaceuticals Raises $72M to Develop MASH, Obesity and Diabetes Drugs

Shanghai-based biotech Cascade Pharmaceuticals announced it has secured $72 million (about 500 million yuan) in new funding to advance its pipeline targeting metabolic-associated steatohepatitis (MASH), obesity, and diabetes. The capital will support preclinical and clinical development of its drug candidates.

ILiAD Biotechnologies Secures $115M Series B to Advance Whooping Cough Vaccine

ILiAD Biotechnologies announced an oversubscribed $115 million Series B financing on Tuesday. The new capital will fund pivotal Phase 3 trials for its whooping cough vaccine, accelerating development and potential market entry.

FDA Rejects Regenxbio's Hunter Syndrome Gene Therapy

The U.S. Food and Drug Administration has officially rejected Regenxbio's investigational gene therapy for Hunter syndrome, a severe X‑linked lysosomal storage disorder. The agency cited gaps in efficacy data and unresolved safety signals from the early‑stage clinical program. Regenxbio had...

With Scant Data, RFK Jr. Credits Trump for Higher European Drug Prices

Robert F. Kennedy Jr., serving as HHS Secretary, reiterated his claim that President Donald Trump's personal intervention and the threat of tariffs forced European nations to raise drug prices. He offered no empirical evidence to substantiate the assertion, and analysts...

QuantX Raises $85M Series B From Lilly, Sanofi Ventures

QuantX Biosciences, a China‑American biotech, announced an $85 million Series B financing round led by the venture arms of Eli Lilly and Sanofi. The capital will fund the company’s immunology pipeline, which targets several high‑profile immune‑modulating proteins. The round underscores growing pharma interest...

Despite FDA’s Crackdown, Pharma Is Still Spending Millions on Ads

The FDA launched an aggressive crackdown on pharmaceutical advertising last fall, issuing thousands of warning letters to drugmakers over misleading consumer ads. Despite the heightened scrutiny, the industry continued to pour roughly $2 billion into promotional campaigns, shifting spend toward digital...

Galux Raises $29M Series B; CSL Teams up with Memo

South Korean biotech Galux secured $29 million in a Series B round to accelerate its AI‑driven research platform that designs novel protein therapeutics. The funding, led by regional venture partners, will expand Galux’s computational pipeline and scale up pre‑clinical collaborations. In parallel,...

#ACTRIMS26: Roche’s MS Drug Fenebrutinib Beats Ocrevus, Cutting Risk of Disability Progression by 12%

Roche announced that its Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib achieved non‑inferior efficacy to the company’s blockbuster Ocrevus in a Phase 3 trial for primary progressive multiple sclerosis (PPMS). The oral agent lowered the risk of confirmed disability progression by 12%...

Takeda, Iambic Sign Multiyear R&D Deal for AI Drug Discovery

Takeda Pharmaceutical announced a multi‑year research agreement with San Diego biotech Iambic to develop AI‑driven small‑molecule drug candidates. The collaboration merges Takeda’s therapeutic expertise with Iambic’s generative AI platform to accelerate hit identification and lead optimization. Joint R&D labs, data...

Novo Nordisk Sues Hims over Wegovy Patent Infringement, Considers Seeking 'Hundreds of Millions' In Damages

Novo Nordisk has filed a federal lawsuit against Hims Inc., alleging that the company infringed on patents covering Wegovy, Novo's flagship semaglutide obesity treatment. The complaint seeks damages in the “hundreds of millions” of dollars, reflecting the high commercial stakes...

Lilly Returns to Innovent to Partner on Cancer and Immune Diseases

Eli Lilly has deepened its alliance with China‑based Innovent Biologics, signing a new agreement that includes a $350 million upfront payment. The partnership will focus on co‑developing bispecific antibody candidates targeting oncology and immunology indications. Both companies will share development costs, milestone...

QuantX Biosciences Secures $85M Series B Funding Led by Lilly and Sanofi Ventures

China‑American biotech QuantX Biosciences announced a $85 million Series B round, led by the venture arms of Eli Lilly and Sanofi. The funding will accelerate its immunology pipeline targeting key immune‑related diseases. The round highlights strong investor interest in biotech innovations.

#ACTRIMS26: Sanofi Unpacks Data From a Failed Phase 3 Tolebrutinib Trial in PPMS

Sanofi disclosed results from its Phase 3 trial of the BTK inhibitor tolebrutinib in primary progressive multiple sclerosis (PPMS). The study failed to meet its primary endpoint of slowing disability progression, and secondary outcomes showed no meaningful benefit. Safety data...

US Calls for DOJ Investigation of Hims over GLP-1 Drugs

The U.S. government has referred tele‑health firm Hims & Hers to the Department of Justice for a formal investigation into its GLP‑1 weight‑loss program. Hims, which recently launched a compounded version of GLP‑1 drugs to compete with Novo Nordisk’s market‑leading injectables, is...

TrumpRx Launch Falls Flat for some, Citing Generic Access

President Donald Trump unveiled TrumpRx, a direct‑to‑consumer drug platform promising to let Americans purchase prescription medicines without traditional insurance intermediaries. The rollout was framed as a fulfillment of broken political promises to lower drug costs. However, early feedback highlights that...

HHS Drops Legal Fight over Blocked 340B Rebate Pilot

The U.S. Department of Health and Human Services has abandoned its legal challenge to a federal court’s injunction that halted a proposed 340B drug‑price rebate pilot. The pilot, designed by the Trump administration to test new rebate mechanisms for hospitals...

Orphan Drug Tweak in US Spending Bill Will Make Life Easier for the FDA

President Donald Trump signed the federal spending bill preserving the FDA’s ability to grant a seven‑year exclusivity period for orphan drugs that receive new indications. The provision reverses earlier suggestions to shorten the exclusivity term, embedding the policy in the...

Agomab, SpyGlass Cap Biggest Week for Biotech IPOs Since 2021

Biotech IPO activity is rebounding as Agomab Therapeutics and SpyGlass Pharma launch public offerings on Friday. Agomab, a fibrosis‑focused company, aims to raise capital to advance its antibody candidates, while SpyGlass seeks funding for its eye‑disease pipeline. The combined debut...

UniQure Pauses Higher Doses in Fabry Study; Aro Shares Pompe Data

UniQure announced a pause on the mid‑ and high‑dose cohorts of its Fabry disease gene‑therapy trial after two participants receiving 4×10^13 genome copies per kilogram experienced safety concerns. The low‑dose arm will continue while the company conducts a detailed safety...

Geoff McDonough's Big Plans for NodThera's NLRP3; Enhertu Leader Steps Down at Daiichi

Former Generation Bio CEO Geoff McDonough has joined biotech NodThera to accelerate its NLRP3 inflammasome program, targeting a Phase 3 trial launch next year. The move underscores NodThera’s ambition to capture a fast‑growing market for anti‑inflammatory therapies. In parallel, Daiichi...

Roivant Spinout Priovant Touts Phase 2 Brepocitinib Data in Cutaneous Sarcoidosis

Priovant Therapeutics, a Roivant spin‑out, announced that brepocitinib – an experimental immune modulator inherited from Pfizer – achieved its primary efficacy endpoint in a Phase 2 trial for cutaneous sarcoidosis. The study demonstrated statistically significant reductions in skin lesion severity and...

Post-Hoc Live: Analyzing the Novo Vs. Hims GLP-1 Showdown

Post‑Hoc Live hosted a deep‑dive into the emerging rivalry between Novo Nordisk and Hims & Hers over GLP‑1 therapies. Novo, the long‑time market leader with drugs like Ozempic and Wegovy, faces a new challenger as Hims rolls out a lower‑priced...

Illumina Bets on Healthcare After Trump Administration's NIH Funding Disruptions

Illumina announced a strategic pivot toward healthcare customers after the Trump administration’s disruptions to NIH funding slashed research‑sector spending. The company will expand its clinical‑grade sequencing platforms, accelerate partnerships with diagnostic labs, and pursue new reimbursement pathways. Illumina projects its...

Agomab Therapeutics and SpyGlass Pharma Set to IPO on Friday

Fibrosis‑focused Agomab Therapeutics and eye‑disease company SpyGlass Pharma announced they will go public on Friday, marking a significant week for biotech IPOs. The offerings are expected to boost the biotech sector's comeback after a slowdown.

FDA Chief Makary Takes Aim at Hims' Compounded Wegovy Pill Plans

FDA Commissioner Marty Makary publicly warned Hims & Hers that the agency will act quickly against its plan to compound Wegovy, the popular semaglutide weight‑loss injection. The warning follows reports that the telehealth firm intends to sell a lower‑cost, compounded...

Generate:Biomedicines Files for IPO to Commercialize AI-Driven Drugs

Generate:Biomedicines, a Flagship Pioneering-backed AI bio startup, has filed for an initial public offering just nine days after dosing its first patient in a Phase 3 trial. The filing signals the company’s move to raise capital and bring AI-driven drug...

Veradermics Surges 122% on Debut as Biotech Goes Public

Biotech firm Veradermics, developing an oral form of Rogaine, completed its initial public offering, with its shares jumping 122% on the first day of trading. The strong debut reflects investor enthusiasm for the growing aesthetics market and the company's innovative...

Angitia Biopharma Secures $130M Series D to Advance Musculoskeletal Drug Pipeline

US-China biotech Angitia Biopharmaceuticals announced a $130 million Series D financing to support three biologics in clinical testing for musculoskeletal diseases. The funding will advance its pipeline, including a candidate that previously fell short at Ultragenyx, highlighting investor confidence in...

Eikon Therapeutics Announces IPO Amid Valuation Cut

Bay Area biotech startup Eikon Therapeutics is preparing for an initial public offering, shifting from its $1 billion fundraising history. The analysis highlights a significant valuation cut as the company moves toward going public, marking a major event in the biotech...

Menlo Ventures and A16z Back AI Startup Phylo in Undisclosed Funding Round

Menlo Ventures and Andreessen Horowitz (a16z) have invested in Phylo, an AI scientist startup founded by Stanford researchers Le Cong, Yuanhao Qu, Kexin Huang, and Jure Leskovec. The funding round was announced on February 3, 2026, with undisclosed terms.

Premise Health to Merge with Crossover Health to Expand Employer Clinics

Premise Health, an advanced primary care provider, announced a merger with Crossover Health, which runs on‑site health clinics for large employers such as Google and Amazon. The combined company aims to broaden its employer clinic network and help control rising...

Agomab Therapeutics Targets $182M Nasdaq IPO to Fund Fibrosis Pipeline

Belgian biotech Agomab Therapeutics announced plans for a Nasdaq IPO to raise approximately $182 million in net proceeds. The capital will support the development of its fibrosis drug pipeline, with the company aiming to sell 12.5 million shares. The offering...

Cellares Secures $257M Series D Funding to Accelerate Global Expansion and Target 2027 IPO

Clinical-stage cell therapy manufacturer Cellares announced a $257 million Series D funding round to support its global expansion and commercial rollout. The capital will also fund preparations for a planned initial public offering in 2027, highlighting investor confidence in its...

Veradermics Targets $181.8M Net Proceeds in Upcoming IPO

Biotech firm Veradermics, developing an oral version of Rogaine, announced plans to go public and raise approximately $181.8 million in net proceeds. The proposed IPO will fund late‑stage testing and commercialization of its hair‑loss treatment.

TRexBio Raises $50M in Series B Extension for Treg Clinical Development

Bay Area biotech TRexBio announced an additional $50 million to its 2024 Series B round, aimed at advancing its pipeline of regulatory T cell (Treg) candidates into clinical trials. The funding will support further development and expansion of its immunotherapy...

Insilico Medicine Secures $120M Drug Discovery Pact with Qilu Pharma

Insilico Medicine announced a $120 million partnership with Chinese pharmaceutical firm Qilu Pharma to develop cardiometabolic therapies. The collaboration will leverage Insilico's AI-driven drug discovery platform to accelerate the identification of novel candidates. The deal highlights growing interest in AI-powered...

Wisp Acquires Sexual Health Startup TBD Health

Virtual women's health platform Wisp announced the acquisition of sexual healthcare startup TBD Health, expanding its tele‑health services. The deal, reported on Jan. 27, 2026, aims to broaden Wisp's offerings in women's sexual health.

Boehringer Ingelheim to Acquire IBD Bispecific From Simcere for €42M

German pharma Boehringer Ingelheim has agreed to pay €42 million upfront to Shanghai-based Simcere Pharmaceutical for an IBD bispecific drug candidate, marking a new partnership in immunology.

BioMarin Veterans Launch New Biotech, Raise $82M for Rare Disease Drug Development

Former BioMarin executives have founded a new biotech focused on rare disease therapeutics. The startup announced an $82 million fundraising round to support development of orphan drugs. The capital will be used to acquire and advance promising rare disease candidates.

Erasca Announces Upsized Public Offering of Common Stock

Erasca announced the pricing of an upsized public offering of its common stock, aiming to raise over $500 million. The offering, part of a broader $500M+ target for several biotech firms, was disclosed in a press release on Jan. 22,...

Claim Health Secures $4.4M Funding to Streamline Home Care Payments

Claim Health, a health‑tech startup, announced a $4.4 million fundraising round to develop AI‑driven solutions that automate payment processes for home‑care providers. The capital will support product development and scaling, with investors not disclosed at the time of the announcement.

Exciva Secures $59M Series B Funding to Advance Alzheimer’s Agitation Drug

Exciva announced a €51 million ($59 million) Series B financing round to fund Phase 2 testing of its candidate drug targeting agitation in Alzheimer’s disease. The capital will support clinical development and expand the company's pipeline.

Shionogi Acquires Pfizer's Stake in ViiV, Doubling Its Ownership

Pfizer announced it will exit the HIV specialist joint venture ViiV, which it co‑founded with GSK. Shionogi will take over Pfizer’s share, doubling its stake in the company. The move reshapes ViiV’s ownership and strengthens Shionogi’s position in the HIV...

GSK to Acquire RAPT for $2.2B

GlaxoSmithKline (GSK) announced a $2.2 billion acquisition of biotech firm RAPT, securing its food allergy candidate. The deal was unveiled at the JP Morgan Healthcare Conference, marking a major M&A move in the pharma sector.

AbbVie Acquires Drug-Device Factory

Pharmaceutical giant AbbVie announced the acquisition of a drug-device manufacturing facility, expanding its presence in the medical device sector. The deal was reported on January 15, 2026, with financial terms undisclosed.

Eli Lilly and Nvidia Sign Five‑year, up to $1 Billion AI Laboratory Deal

Eli Lilly and Nvidia have entered a five‑year partnership valued at up to $1 billion to create an AI laboratory aimed at accelerating drug discovery. The collaboration builds on a prior agreement to build pharma’s largest supercomputer and will leverage Nvidia’s...

Aktis Oncology Lands Biotech's First IPO of 2026, Raising $318M

Aktis Oncology, a radiopharmaceutical startup partnered with Eli Lilly, announced its initial public offering on the Nasdaq, raising $318 million. The IPO marks the first biotech offering of 2026, positioning the company for growth in the radiopharma sector.

Medipost Raises $140M to Expand Korean Stem Cell Therapy to US and Japan

South Korean biotech Medipost announced a $140 million fundraising round to commercialize its allogeneic cell therapy, approved in South Korea since 2012, in the United States and Japan. The capital will support regulatory approvals and market entry in these regions.

Alveus Therapeutics Raises $159.8M in Series A to Expand Obesity Drug Pipeline

Alveus Therapeutics announced a $159.8 million Series A funding round on Thursday, aiming to accelerate its obesity drug development and challenge market leaders like tirzepatide and semaglutide. The capital will support the company's push into the space dominated by MariTide....

Vizgen Raises $48M in Series E Round to Expand Spatial Biology and Multiomics Tools

Vizgen, a startup developing spatial biology and multiomics mapping technologies, announced a $48 million Series E funding round. The capital will be used to accelerate product development and market expansion. The round underscores continued investor interest in biotech innovation.

Beacon Therapeutics Raises $75M Series C Led by Goldman Sachs Alternatives

Beacon Therapeutics announced a $75 million Series C financing round to advance its vision treatment pipeline. The round was led by Goldman Sachs Alternatives, with participation from a managing partner of the firm’s life sciences team. The funding aims to...

French Biotech Enodia Therapeutics Raises €20.7M with Pfizer Backing

Enodia Therapeutics, a French biotech founded in February, announced it has raised €20.7 million (approximately $24 million) to develop protein degrader technology. The financing was aided by pharmaceutical giant Pfizer, marking a significant early-stage corporate investment in the company.

Boltz Secures $28M Seed Funding to Build Open AI Models in Biology

Biotech startup Boltz announced a $28 million seed round to develop open AI models for biology. The funding will support the creation of large language models that predict biomolecular structures, building on advances like AlphaFold. The round highlights growing investor...

Servier Launches €200M Corporate Venture Capital Unit for European Biotech Startups

French pharmaceutical group Servier announced the creation of a corporate venture capital unit focused on European biotech startups, initially funded with about €200 million ($232.9 million). The new VC arm aims to back emerging biotech innovations, joining a wave of large pharma...

Parabilis Medicines Raises $305M to Tackle Undruggable Proteins

Parabilis Medicines announced a $305 million financing round to develop therapies targeting undruggable proteins. The capital will fuel its platform to address challenging protein targets, highlighting strong investor interest in biotech solutions for hard‑to‑drug diseases.